TICKERNERD
Menu
IPSCIPSCHealthcare · Biotechnology

IPSC Stock Forecast: Century Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$1.46
+14.06% on the day

The 5 Wall Street analysts covering Century Therapeutics, Inc. hold a median 12-month price target of $4.5 — +208.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 38 of 100 as at 8 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$231.8M
Ticker Nerd rank
38 / 100
Median analyst target
$4.50
Analysts covering
5
Revenue$0.0
Operating income−$25.4M
Net income−$34.5M
Free cash flow−$20.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−9.3%
1M
−29.5%
YTD
+46.7%
1Y
+150.0%
From 52W high
−50.3%
From 52W low
+214.0%
$0.47
$2.94
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IPSC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Century Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
38 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
86
Size
64
Accruals
63
Quality
58
Issuance
52
Revisions
35
Value
33
Volatility
17
Growth
10

Momentum (86): The shares have been drifting up relative to others.

Growth (10): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

IPSC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IPSC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00Jan 26Apr 26Jul 26Oct 26IPSCHigh $8.00Median $4.50Low $2.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
4 Buy1 Hold0 Sell
Low $2.00Median $4.50High $8.00

The green dot is the last close — the median target sits +208.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
27 May 2026MizuhoInitiatesOutperform$8.00
21 Apr 2026HC Wainwright & Co.MaintainsBuy—
20 Jan 2026Piper SandlerMaintainsOverweight—
17 Nov 2025Leerink PartnersDowngradeMarket Perform—
16 May 2025Chardan CapitalMaintainsBuy—
3 Apr 2025HC Wainwright & Co.MaintainsBuy—
28 Mar 2025GuggenheimReiteratesBuy—
24 Mar 2025Chardan CapitalMaintainsBuy—
21 Mar 2025GuggenheimMaintainsBuy—
20 Mar 2025Piper SandlerMaintainsOverweight—
22 Jan 2025GuggenheimReiteratesBuy—
22 Jan 2025HC Wainwright & Co.ReiteratesBuy—
30 Dec 2024Piper SandlerMaintainsOverweight—
7 Nov 2024Chardan CapitalMaintainsBuy—
6 Nov 2024HC Wainwright & Co.MaintainsBuy—
15 Aug 2024HC Wainwright & Co.MaintainsBuy—
17 June 2024Piper SandlerMaintainsOverweight—
4 June 2024HC Wainwright & Co.ReiteratesBuy—
10 May 2024HC Wainwright & Co.MaintainsBuy—
12 Apr 2024Piper SandlerReiteratesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IPSC appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

IPSC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Century Therapeutics, Inc. returned +150.0% against +16.2% for the S&P 500, dividends included.

IPSC vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400500Jan 26Apr 26Jul 26Oct 26IPSCS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IPSC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Century Therapeutics, Inc. (IPSC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−8.9×

Cheaper than 93% of US stocks

Price / sales
2.1×

Cheaper than 50% of US stocks

Price / book
1.0×

Cheaper than 72% of US stocks

EV / EBITDA
−1.7×

Cheaper than 71% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
−100.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
−9.6%

Higher than 24% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−49.7%

Higher than 21% of US stocks

Return on assets
−23.5%

Higher than 17% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Century Therapeutics, Inc. (IPSC) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Century Therapeutics, Inc. has a market value of $231.8M and an enterprise value of $158.0M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$109.8M.

  • Free cash flow in the twelve months to 30 June 2026: −$88.1M.

  • Shares outstanding: 180.5M.

  • Trailing P/E: −8.9×; forward P/E: −2.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Century Therapeutics, Inc. employs 78 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

IPSC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
IPSCCentury Therapeutics, Inc.$231.8M
38
SABSSAB Biotherapeutics, Inc.$263.0M
39
VOGXVogenx, Inc.$259.8M
2
ACIUAC Immune SA$259.5M
33
IKTInhibikase Therapeutics, Inc.$266.5M
40
VNDAVanda Pharmaceuticals, Inc.$267.8M
47
LCTXLineage Cell Therapeutics, Inc.$256.6M
58

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Century Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IPSC news & analysis

Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026

GlobeNewsWire · 2 Oct 2026positive

Century Therapeutics presented nonclinical data for CNTY-813, its iPSC-derived islet replacement therapy for type 1 diabetes, at EASD 2026. The data demonstrated scalable production, in vivo function, immune evasion, and updated progress toward clinical dosing.

Why it matters — This marks continued advancement of Century's iPSC-based diabetes candidate toward the clinic, showing progress on key development milestones for the company's pipeline.

Century Therapeutics: Competitors May Be Quietly De-Risking Its Biggest Bet

Seeking Alpha · 30 Sept 2026neutral

Century Therapeutics, rated speculative Buy with a $363M equity value, focuses on CNTY-813 for type 1 diabetes, which aims to deliver insulin-producing islets without chronic systemic immunosuppression using Allo-Evasion 5.0 genetic edits. Strong preclinical results and a cash runway into Q1 2029 support the risk/reward, though lack of human data and potential dilution keep conviction low.

Why it matters — IPSC watchers would care because the outlook for its lead CNTY-813 program hinges on whether preclinical promise translates to human data, with cash runway into 2029 and dilution risk shaping the investment case.

Century Therapeutics Appoints Joseph Truitt to Board of Directors

GlobeNewsWire · 9 Sept 2026neutral

Century Therapeutics announced the appointment of Joseph Truitt to its Board of Directors. The announcement was made public on September 9, 2026.

Why it matters — A new board appointment brings additional experience and governance perspective to the company as it continues developing iPSC-derived cell therapies.

Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

GlobeNewsWire · 12 Aug 2026positive

Century Therapeutics reported second quarter 2026 financial results, including $197.2 million in cash with a runway into the first quarter of 2029. The company completed a pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy for type 1 diabetes, with an IND submission on track for the fourth quarter of 2026, and remains on track to advance CNTY-308 into the clinic this year.

Why it matters — For IPSC watchers, the progress of CNTY-813 toward an IND, positive preclinical data, and the planned clinical advancement of CNTY-308 represent key developmental milestones for the company's iPSC-derived cell therapy pipeline.

FAQ

Frequently asked questions about IPSC stock

What is the IPSC stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Century Therapeutics, Inc. have a median 12-month price target of $4.5, with estimates ranging from $2 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IPSC stock a buy right now?

Of the 5 analysts covering Century Therapeutics, Inc., 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Century Therapeutics, Inc. 38 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IPSC?

As at 8 Oct 2026, Century Therapeutics, Inc. ranks 38 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (86 of 100).

Will IPSC stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +208.2% from the last close, and Ticker Nerd's factor model ranks Century Therapeutics, Inc. 38 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IPSC stock forecast for 2030?

No analyst covering Century Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IPSC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $8 over the next 12 months.

How has IPSC stock performed over the past year?

Century Therapeutics, Inc. returned +150.0% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Century Therapeutics, Inc. do?

Century Therapeutics Inc is a biotechnology company focused on developing allogeneic cell therapies for cancer, autoimmune diseases, and other immune-mediated conditions. The company uses induced pluripotent stem cell technology to create off-the-shelf immune cell products, including natural killer and T cell therapies designed to target solid tumors and hematological malignancies.

What is the latest news on IPSC?

The most recent item we track (GlobeNewsWire, 2 Oct 2026): "Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026". Century Therapeutics presented nonclinical data for CNTY-813, its iPSC-derived islet replacement therapy for type 1 diabetes, at EASD 2026. The data demonstrated scalable production, in vivo function, immune evasion, and updated progress toward clinical dosing.

Company

About Century Therapeutics, Inc.

Century Therapeutics Inc is a biotechnology company focused on developing allogeneic cell therapies for cancer, autoimmune diseases, and other immune-mediated conditions. The company uses induced pluripotent stem cell technology to create off-the-shelf immune cell products, including natural killer and T cell therapies designed to target solid tumors and hematological malignancies. Its current pipeline also includes programs in type 1 diabetes and other autoimmune applications, reflecting a broader effort to apply engineered cell therapy platforms across multiple disease areas. Century Therapeutics combines stem cell derivation, gene editing, and immune-evasion technologies to support scalable manufacturing and differentiated product development. Headquartered in Philadelphia, Pennsylvania, Century Therapeutics operates in the advanced biotechnology segment of the healthcare market, where it develops next-generation cellular medicines intended for clinical use.

CEO Dr. Brent Pfeiffenberger M.B.A., Pharm.D. · 78 employees · United States · https://www.centurytx.com